Supportive Medicines for Adults Receiving Marketed CAR-T Cell Therapy

Anne Black, Regional QA Specialist Pharmacist, NHS SPSPublished

This document provides expert clinical pharmacy guidance on supportive medicines in order to facilitate the treatment of complex CAR-T Cell Therapy patients.

About

Chimeric antigen receptor-T (CAR-T) cell therapies are Advanced Therapy Medicinal Products.  There are novel systemic anti-cancer therapies in which autologous or allogeneic T cells are engineered to express a chimeric antigen receptor which targets membrane antigens present on indicated cancer cells.

Purpose

Prior to receiving CAR-T cell therapy, patients will receive lymphodepletion chemotherapy.  CAR-T cell therapy and lymphodepletion regimes can increase the likelihood of certain side effects and infections so supportive medicines are recommended.

These consensus recommendations, prepared by the Clinical Pharmacy subgroup of the Pan UK Pharmacy Working Group for Advanced Therapy Medicinal Products (ATMPs), relate to supportive medicines recommended for adults receiving licensed CAR-T cell therapy.

Attachments